The global closed-loop spinal cord stimulation device market size was valued at USD 412.00 million in 2025 and is projected to grow from USD 469.27 million in 2026 to USD 1329.26 million by 2034, registering a CAGR of 13.90% during the forecast period (2026–2034). North America dominated the closed-loop spinal cord stimulation device market with a share of 56.6% in 2025.
Closed-loop spinal cord stimulation devices are implantable neurostimulation systems designed to deliver electrical stimulation to the spinal cord while continuously measuring neural responses and adjusting stimulation parameters through a feedback mechanism. Closed-loop spinal cord stimulation devices are tracked under HSN Code 9018 (instruments and appliances used in medical or surgical sciences) and SIC Code 3841 (surgical and medical instruments and apparatus).
The closed-loop spinal cord stimulation device market demand is supported by the rising prevalence of chronic pain, increasing adoption of spinal cord stimulation, and growing development of feedback-controlled neurostimulation technologies. Healthcare providers are adopting closed-loop systems that measure neural responses and automatically adjust stimulation to maintain targeted spinal cord activation, contributing to closed-loop spinal cord stimulation device market growth.
• 2025 Market Size: USD 412.0 Billion• 2026 Market Size: USD 467.62 Billion• 2034 Projected Market Size: USD 1,329.23 Billion• Forecast Period: 2026–2034• Base Year: 2025• Market CAGR (2026–2034): 13.90%
• Largest Regional Market (2025): North America• North America Market Share (2025): 56.6%• Fastest-growing Region: Asia Pacific• Asia Pacific CAGR (2026–2034): 14.6%
By Lead Type
• Leading Segment: Percutaneous Leads• Market Share in 2025: 61.8%
By Application
• Fastest-growing Segment: Complex Regional Pain Syndrome• CAGR: 14.2% (2026–2034)
By End Use
• Leading Segment: Hospitals• Market Share in 2025: 58.4%
Download a Free Sample To learn more about this report,
Expansion of Physiologic Feedback Controlled Stimulation
The closed-loop spinal cord stimulation device market analysis shows that the closed-loop spinal cord stimulation systems are using neural feedback signals to adjust stimulation according to the spinal cord's response. This approach maintains more consistent stimulation when patient movement or physiological conditions change. The development improves the precision and stability of spinal cord stimulation therapy.
Integration of Assisted Programming Software
Closed-loop stimulation systems are incorporating software tools that help clinicians select, adjust, and manage therapy settings. These tools simplify programming and support more efficient configuration of stimulation parameters. This integration improves the clinical workflow for setting up and managing spinal cord stimulation therapy.
Supply chain disruptions are expected to have a substantial impact on the closed-loop spinal cord stimulation device market share, as dependence on specialized implantable electronics, neural sensing leads, sterile components, and qualified suppliers can create production delays and limited device availability. The market is likely to follow a capacity-constrained recovery pattern, as specialized components require strict validation and regulatory approval before replacement suppliers or modified components can be introduced. The market is expected to grow at a CAGR of 13.90%, but supply chain constraints could approximately lower this by 0.5 percentage points, resulting in short-term growth of around 13.40%. As supply conditions normalize through expanded qualified supplier capacity, improved availability of implantable electronics and leads, stable component manufacturing, and more reliable medical device logistics, closed-loop spinal cord stimulation device market growth is expected to gradually return to 13.90%.
The closed-loop spinal cord stimulation device market forecasts strategic investment activity driven by adaptive stimulation technologies, real-time neural feedback, AI-enabled pain management, personalized spinal cord stimulation, and next-generation implantable neuromodulation systems. In January 2025, Saluda Medical received USD 100 million in financing led by Redmile Group, with participation from Wellington Management, TPG Life Sciences Innovation, Fidelity Management & Research Company, Action Potential Venture Capital, T. Rowe Price Associates, and Piper Heartland Healthcare Capital, to advance commercialization of its Evoke System, a physiologic closed-loop, dose-control spinal cord stimulation system for chronic pain.
Refractory Neuropathic Pain and Diabetic Nerve Damage Drive Market
Persistent neuropathic pain that remains inadequately controlled with conventional treatment creates a need for advanced chronic pain treatment. CMS states that spinal cord stimulation (SCS) may be covered for chronic intractable pain and is particularly suited to neuropathic pain, supporting the clinical role of neurostimulation in this patient group.
Diabetic peripheral neuropathy increases the number of patients requiring advanced treatment for persistent nerve related pain. Greater use of SCS for this condition expands the patient base seeking device based pain therapy and creates additional clinical demand for neuromodulation.
MRI Access Restrictions and High Implant Power Replacement Costs Constrain Market Expansion
MRI compatibility restrictions can limit imaging options for some patients using implantable medical devices. Specific MRI conditions or device requirements may complicate access to diagnostic imaging for patients receiving long term pain therapy.
Battery replacement requirements add to the long term management costs of implantable pulse generators. Replacement procedures require additional clinical visits and device related intervention, increasing the burden of chronic pain management over the implant lifecycle.
Smaller Implant Designs and Specialist Training Services Expand Growth Opportunities for Closed-Loop Spinal Cord Stimulation Market Players
The development of smaller implant designs opens growth opportunities for closed-loop spinal cord stimulation manufacturers, neuromodulation-device developers, and implantable medical-device suppliers by enabling more compact systems designed to improve patient comfort and provide greater flexibility in implant placement. Smaller neurostimulators can also support product differentiation where patients and clinicians prioritize reduced implant size alongside advanced sensing and closed-loop stimulation capabilities. Medtronic’s Inceptiv system demonstrates this direction through a compact, thin implant combined with closed-loop sensing.
The expansion of specialist training services opens revenue avenues for SCS manufacturers, neuromodulation training providers, clinical education companies, and specialized pain-care centers. Training programs can cover closed-loop programming, implantation techniques, patient selection, device optimization, and therapy management, creating opportunities for manufacturers and training providers to offer structured education alongside increasingly sophisticated SCS systems.
Uneven Specialist Center Access and Alternative Neuromodulation Competition Hinder Growth
Limited access to specialist SCS centers can restrict availability of implantation, programming, and follow up services in smaller cities and underserved regions. This concentration of advanced spinal cord stimulation (SCS) care can limit broader access to implantable medical devices and slow geographic market expansion.
Alternative neuromodulation therapies, including peripheral nerve stimulation and other targeted nerve stimulation approaches, compete for chronic pain treatment use and healthcare resources. Broader availability of these options can make differentiation more difficult for manufacturers of pain management devices and implantable pulse generators.
The percutaneous leads segment is expected to grow at a CAGR of 13.2% during the forecast period, driven by their minimally invasive placement and suitability for trial stimulation before permanent implantation. Their less invasive insertion supports broader use in patients undergoing spinal cord stimulation.
The paddle or surgical leads segment is expected to grow at a CAGR of 15.1% during the forecast period, fueled by their ability to provide broader electrical coverage and more targeted stimulation. These characteristics support their use in patients requiring precise treatment of complex pain patterns.
Request Customizationto receive a tailored report.
The failed back surgery syndrome segment accounted for a share of 44.7% in 2025, supported by the persistent pain experienced by patients following spinal procedures and the use of spinal cord stimulation when conventional treatments provide inadequate relief. Closed-loop stimulation can help adjust therapy based on neural responses during treatment.
The complex regional pain syndrome segment is expected to grow at a CAGR of 14.2% during the forecast period, propelled by the need for advanced neuromodulation in patients with persistent neuropathic pain. Closed-loop systems can enable responsive stimulation adjustments for managing changing pain patterns.
The hospitals segment accounted for a share of 58.4% in 2025, owing to the need for specialized facilities and trained clinical teams to perform spinal cord stimulation implantation and programming. Hospitals also provide the multidisciplinary care required for complex chronic pain management.
The ASCs segment is expected to grow at a CAGR of 15.2% during the forecast period, driven by the shift toward minimally invasive procedures in outpatient settings and shorter procedural recovery times.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Medicare Coverage and Adoption of Physiologic Closed-Loop Stimulation Devices
The North America closed-loop spinal cord stimulation device market accounted for the largest regional share of 56.6% in 2025 due to established use of spinal cord stimulation for chronic intractable pain.
The U.S. market is supported by coverage for chronic intractable and neuropathic pain and established percutaneous trial pathways before permanent implantation. The current Medicare coverage framework allows spinal cord stimulation for qualifying chronic pain patients and requires a successful stimulation trial before permanent implantation, supporting continued utilization of neurostimulation devices.
The Canada market benefits from increasing clinical adoption of physiologic closed-loop stimulation for refractory chronic pain. A 2026 Canadian clinical report evaluated closed-loop spinal cord stimulation across multiple chronic pain conditions, documenting patient outcomes and practitioner experience with physiologic feedback based therapy.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Fueled by Surgical Lead Development and Expanded Neuromodulation Applications
The Asia Pacific closed-loop spinal cord stimulation device market is expected to grow at a CAGR of 14.6% during the forecast period, showcasing the fastest-growing regional growth.
The Japan market is driven by spinal stimulation for neurological movement disorders. In July 2026, a Phase II study registered with Japan’s Ministry of Health, Labour and Welfare began evaluating spinal electrical stimulation for refractory gait impairment associated with Parkinson’s disease and progressive supranuclear palsy.
The China market benefits from standardization of implantable neurostimulator requirements. China’s National Medical Products Administration has made YY 0989.3 mandatory, establishing specific requirements for implantable neurostimulators used for electrical stimulation of the central or peripheral nervous system.
The India market is supported by increasing use of spinal stimulation for motor recovery after spinal cord injury. Indian spinal and rehabilitation institutions evaluated spinal epidural electrical stimulation for lower limb motor recovery, supporting broader clinical application of spinal stimulation technologies.
Europe: Growth Propelled by Focus on Managing Complex Regional Pain Care
The Europe closed-loop spinal cord stimulation device market is expected to grow at a CAGR of 13.5% during the forecast period.
The UK market is elevated by the adoption of closed-loop SCS within specialist NHS pain services. NICE reports that the Evoke closed-loop system is currently used in five NHS trusts, indicating integration of closed-loop therapy into the UK clinical care pathway.
The Germany market is supported by spinal cord stimulation for refractory complex regional pain syndrome (CRPS). A AWMF S3 guideline on peripheral nerve injuries recognizes spinal cord stimulation and dorsal root ganglion stimulation for otherwise treatment resistant lower limb CRPS after successful trial stimulation.
Latin America: Market Expansion Driven by Implantable Device Availability and Public Coverage Pathways
The Latin America closed-loop spinal cord stimulation device market is expected to grow at a CAGR of 11.9%. In Mexico, the National Compendium of Health Supplies includes implantable spinal cord stimulators within its listed neurostimulation devices, supporting formal availability for clinical use. In Brazil, spinal cord stimulation has been incorporated into the SUS, with acquisition and implementation steps underway, supporting wider public access to the technology.
Middle East & Africa: Market Development Led by Implant Safety Regulations
The Middle East and Africa closed-loop spinal cord stimulation device market is expected to grow at a CAGR of 10.7% during the forecast period, supported by active implantable device surveillance and demand for advanced treatment of persistent pain after spinal surgery. In the UAE, the Department of Health’s current medical device safety notices include spinal cord stimulation and dorsal root ganglion implantable pulse generators, reflecting ongoing oversight of advanced implantable pain devices.
The closed-loop spinal cord stimulation device market competitive landscape is highly concentrated, with competition largely centered on specialized neuromodulation companies developing implantable systems. Key players such as Medtronic plc and Saluda Medical Pty Ltd. are collectively estimated to account for approximately 80–85% of the global closed-loop spinal cord stimulation device market share.
Established participants compete primarily through closed-loop sensing accuracy, adaptive stimulation algorithms, implant design, battery performance, MRI compatibility, regulatory clearances, and patient outcomes. Emerging and niche companies in the closed-loop spinal cord stimulation device market ecosystem compete through advanced neural sensing, automated programming, smaller implantable systems, and specialized approaches for chronic pain management.
June 2026: The FDA approved a PMA supplement for the Evoke SCS System's implanted closed-loop stimulator, covering updated therapy and telemetry firmware configurations.
April 2026: Saluda Medical reported a case series demonstrating real-time adjustment of stimulation using ECAP-controlled closed-loop SCS in two patients with chronic lumbar radiculopathy and axial low-back pain.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Cochlear Implants Market Size, Share, Growth, Forecast, 2034
Cold Pain Therapy Market Size, Share, Growth, Analysis, Report, 2034
Artificial Organs Market Size, Share, Growth, Forecast, 2034
Automated External Defibrillators Market Size, Share, Growth, 2034
Brain Monitoring Market Size, Share, Growth, Forecast, 2034
Breathwork Therapy Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com